Clinical Trial

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-13; most recent amendment 2025-09-18.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT07079228
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Pancreatic Cancer
Enrollment 602 participants
Start Date 2025-09-08
Primary Completion 2028-12 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-23